Grah Josip, Samija Mirko, Juretić Antonio, Sarcević Bozena, Sobat Hrvoje
Department of Radiation Oncology, University Hospital for Tumors, Zagreb, Croatia.
Coll Antropol. 2008 Sep;32(3):731-6.
The aim of this study was to explore the expression of cancer/testis tumor associated antigens (C/T TAAs) MAGE-A 3/4 and NY-ESO-1 in lung squamous cell carcinoma and adenocarcinoma, and to evaluate their association with the standard clinical-pathological features of surgically treated lung cancer patients. The study included 80 patients with non-small cell lung cancer (40 adenocarcinomas, 40 squamous cell carcinomas) who had undergone surgery in the period between 2002 and 2005. The MAGE-A3/4 and NY-ESO-1 antigen expression was analyzed immunohistochemically (IHC). The results showed MAGE-A3/4 and NY-ESO-1 positive staining in 65.1% and 23.3% of squamous cell carcinomas and 18.9% and 10.8% of adenocarcinomas, respectively. A statistically higher MAGE-A3/4 expression was observed in planocellular bronchial carcinoma (p < 0.001), while no difference was found in the expression of NY-ESO-1 in adenocarcinoma and planocellular carcinoma (p = 0.144). A significant association was found between the MAGE-A3/4 expression and presence of tumor necrosis in squamous cell cancer specimens (p = 0.001), but not in adenocarcinoma (p = 0.033). A statistically significant association was noted between the NY-ESO-1 expression and positive hilar and mediastinal lymph nodes in adenocarcinoma (p = 0.025) whereas it was not the case in squamous cell carcinoma. Non-small cell lung cancer frequently expresses cancer/testis tumor associated antigens. Our results demonstrate that the MAGE-A3/4 and NY-ESO-1 expression was significant associated with prognostic factors of poor outcome of disease (presence of tumor necrosis and lymph node metastasis). As C/T antigens are important for inducing a specific immune reaction in lung cancer patients, there is an intention to form a subgroup of patients in the future, whose treatment would be enhanced by specific immunotherapy based on the observed scientific results.
本研究旨在探讨癌/睾丸肿瘤相关抗原(C/T TAAs)MAGE-A 3/4和NY-ESO-1在肺鳞状细胞癌和腺癌中的表达情况,并评估其与接受手术治疗的肺癌患者标准临床病理特征的相关性。该研究纳入了2002年至2005年间接受手术的80例非小细胞肺癌患者(40例腺癌,40例鳞状细胞癌)。采用免疫组织化学(IHC)方法分析MAGE-A3/4和NY-ESO-1抗原的表达情况。结果显示,MAGE-A3/4和NY-ESO-1在鳞状细胞癌中的阳性染色率分别为65.1%和23.3%,在腺癌中的阳性染色率分别为18.9%和10.8%。在扁平细胞支气管癌中观察到MAGE-A3/4表达在统计学上更高(p < 0.001),而在腺癌和扁平细胞癌中NY-ESO-1的表达未发现差异(p = 0.144)。在鳞状细胞癌标本中,发现MAGE-A3/4表达与肿瘤坏死的存在之间存在显著相关性(p = 0.001),但在腺癌中无相关性(p = 0.033)。在腺癌中,NY-ESO-1表达与肺门和纵隔淋巴结阳性之间存在统计学上的显著相关性(p = 0.025),而在鳞状细胞癌中则不然。非小细胞肺癌经常表达癌/睾丸肿瘤相关抗原。我们的结果表明,MAGE-A3/4和NY-ESO-1的表达与疾病预后不良的危险因素(肿瘤坏死和淋巴结转移的存在)显著相关。由于C/T抗原对于诱导肺癌患者的特异性免疫反应很重要,未来有意形成一个患者亚组,根据观察到的科学结果,其治疗将通过特异性免疫疗法得到加强。